Journal
CURRENT OPINION IN PULMONARY MEDICINE
Volume 20, Issue 1, Pages 53-59Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCP.0000000000000006
Keywords
asthma; FeNO; management; phenotypes; wheeze
Categories
Funding
- Mundipharma
- AstraZeneca
- Chiesi
- Novartis
Ask authors/readers for more resources
Purpose of reviewThis review focuses on the most recent studies investigating fractional nitric oxide concentration in exhaled breath (FeNO) as a useful biomarker for identifying specific phenotypes in asthma and as a tool for asthma diagnosis, monitoring and clinical decision-making.Recent findingsOn the basis of the current literature, it has been highlighted that FeNO is a clinically relevant marker in various clinical aspects of asthma: FeNO is a predictor for developing asthma in persistent rhinitis or in infants with respiratory symptoms; FeNO contributes to identification of asthma phenotypes in both children and adults, also in relation to severity; FeNO is useful in monitoring the effectiveness of inhaled corticosteroids (including compliance) and biologic treatments like omalizumab; FeNO, in conjunction with symptom registration and lung function measurements, contributes to asthma diagnosis and optimizes asthma management.SummaryFeNO provides further information in distinguishing different phenotypes in asthma, allowing a much more appropriate control of the disease, especially in patients with difficult/severe asthma. In the future, it would be interesting to shed light on the hidden biological mechanisms responsible for low or normal FeNO values in symptomatic asthmatic patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available